🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Despicable. As families grieve, Trump should be leading, not lying. We put safety first, drove down close calls, grew Air Traffic Control, and had zero commercial airline crash fatalities out of millions of flights on our watch. President Trump now oversees the military and the

I, and every scientist I've talked to, believe the end result of this devastating cut will be that Universities will simply pass on the buck to investigators. Many of us fervently agree that university administrations & bureaucracy should be downsized and reformed. This maneuver

An exciting year for ADCs with practice-changing potential. Sequencing and toxicity mitigation/management will remain important concepts with further integration into the BC treatment landscape!

Delighted to share our paper investigating PET & HER2 biomarkers from TBCRC026 trial, aiming to personalize therapy for patients with early HER2+ breast cancer. Thanks to all co-authors and collaborators Translational Breast Cancer Research Consortium Johns Hopkins Kimmel Cancer Center Roisin Connolly Breakthrough Cancer Research

🧵 Twenty-five years ago, it was common to hear complaints about a “drug lag”—the perception that Europeans routinely enjoyed medical advances years before their American counterparts. Through a generation of congressional actions, investments in expertise and hiring, and careful

Our paper in JCO Precision Oncology describes Digital Spatial Profiling analysis of HER2+ tumors, revealing novel insights into tumor & immune microenvironment -implications for biomarker discovery & tailoring of tx 💉🎯 Thanks to Roisin Connolly, Translational Breast Cancer Research Consortium Johns Hopkins Kimmel Cancer Center Breakthrough Cancer Research

ADCs are rapidly moving to earlier line treatment for breast cancer. Will likely reach the (neo)adjuvant setting soon. Here’s a recap of key ADC phase 3 trials expected to shape practice in the next future:

Congratulations Hope Rugo. City of Hope is lucky to have you.

It’s been a fantastic first day at MD Education’s Inaugural Breast Cancer US Focus Meeting 2025 in Boston. Excellent presentations and engaging panel discussions set a high bar for the rest of the event. All content will be available online for 12 months — Sign up here:

Day 1 of the inaugural MD Education’s #BreastCancer US Focus Meeting, chaired by Dr. Sara Tolaney (Sara Tolaney) and Dr. Virginia Kaklamani (VIRGINIA KAKLAMANI), was a success! The day was filled with outstanding presentations and dynamic panel discussions, with more to come tomorrow.

One week to #ASCO25. Which will be an unprecedented ASCO for breast oncologists. Treatment algorithms will change for ALL disease subtypes. ADCs will climb to earlier lines of treatment. Paradigms will be challenged. Here’s my list of top 10 abstracts. See you in Chicago! #bcsm

ASCO ended over a week ago, but we're still thinking about how great it was! Highlights included: -Soni Smith MD's first ASCO conference on the Board of Directors -4 (!!) of our University of Chicago Hem/Onc Fellows winning YIAs -Rita Nanda as a FASCO recipient -30+ posters/presentations!

A comprehensive review about the role of tumor microenvironment on the immunotherapy response! OncoAlert Nature Cancer #Cancer #Oncology #MedTwitter nature.com/articles/s4301…

10 Key Milestones in The Development of ADCs – Curated by Paolo Tarantino and Raffaele Colombo Paolo Tarantino Raffaele Colombo oncodaily.com/opinion/adcs-3… #Health #Oncology #OncoDaily #Medicine #Cancer CancerWorld

Our amazing social workers Julie & Stephanie from the Supportive Oncology team presented last week at the Association for Oncology Social Work conference about the team's approach to addressing food insecurity! #CancerCare #SocialWorkers UChicagoCancerCenter UChicago Medicine

Study that went under the radar at ASCO. WBRT with hippocampal sparing and memantine versus SRS for 5-20 brain metastases. Same Overall survival, Lower Symptom Burden and Life Interference with SRS, Better KPS with SRS. New standard of care! Congrats Dr. Aizer on this amazing

UChicago Medicine is searching for a Director of Supportive Oncology. The appointee will be responsible for the development, expansion, management, and alignment of services reflected in a patient’s cancer journey. If interested, please apply! apply.interfolio.com/163026

The University of Chicago’s Department of Radiology seeks an accomplished radiologist and visionary leader to serve as Section Chief of Breast Imaging at the rank of Associate Professor or Professor. For more info or to apply please see: apply.interfolio.com/169547

Welcome 🎉 We're so glad you're all here!!

What “fancy” ADCs are in the pipeline? Rafeh Naqash, MD reviews the rapidly evolving field of ISACs, DACs, bsADCs and further innovative ways of utilizing the ADC paradigm to selectively deliver anticancer molecules to tumors. Many bumps along the way, a lot of hopes for the future